GlassScriptPhysician profile
Christin C Hurt
NPI 1144404898
$9,454.74
in general payments reported to CMS, 2019-2025
30 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,297 · 2020: $1,021 · 2021: $1,667 · 2022: $1,959 · 2023: $1,132 · 2024: $1,266 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,411 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.44 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,065.40 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $940.31 | 2019-2025 | |
| Janssen Biotech, INC. | $616.10 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $584.54 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $580.88 | 2019-2025 | Nemluvio, Dysport |
| Pfizer INC. | $507.63 | 2019-2025 | |
| Merz North America, INC. | $500.00 | 2022 | |
| Lilly USA, LLC | $463.68 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Allergan, INC. | $435.23 | 2021-2022 | |
| Leo Pharma INC. | $384.17 | 2019-2025 | Adbry, Anzupgo |
| Almirall LLC | $351.87 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $264.95 | 2019-2023 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $215.42 | 2019-2021 | |
| Revance Therapeutics, INC. | $185.01 | 2024-2025 | Daxxify |
| Ucb, INC. | $170.32 | 2020-2024 | Bimzelx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $157.53 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $128.41 | 2019-2020 | |
| Strata Skin Sciences, INC. | $118.86 | 2020-2024 | Xtrac |
| Dermavant Sciences, INC. | $118.03 | 2022-2024 | Vtama |
| Organon LLC | $117.78 | 2025 | Vtama |
| Genzyme Corporation | $109.20 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $92.32 | 2022-2025 | Sotyktu |
| Dermira, INC. | $72.15 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $53.86 | 2020-2021 | |
| Amgen INC. | $52.92 | 2020-2023 | Otezla |
| Celgene Corporation | $43.87 | 2019 | |
| Journey Medical Corporation | $41.14 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.76 | 2022-2024 | Spevigo |
| Sebela Pharmaceuticals INC. | $32.65 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christin Hurt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.